Close Menu

epilepsy

The firms will conduct PacBio whole-genome sequencing on epilepsy patients to generate variant profiles that can help the development of diagnostic assays.

The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.

Blueprint provides 3,900 targeted single-gene and more than 200 panel tests covering 14 medical specialties, leveraging NGS and bioinformatics methods.

Evogen launched a clinical trial to further validate its proteomic test for distinguishing between epileptic seizures and psychogenic non-epileptic seizures.

Apatagen is developing the aptamer-based test to diagnose human carriers of pork tapeworm and prevent neurocysticercosis, which causes adult-onset epilepsy.

Acquired epilepsy is a form of the neurological disorder that results from other conditions such as stroke, infections, and traumatic brain injury.

The company announced this week the expansion of a genetic testing program for US patients with inherited retinal disease that it has run with partners since 2017.

Evogen's protein biomarker-based test is designed to stratify actively seizing patients from those who have not experienced a recent seizure.

Free genetic testing on a broad gene panel is available to children, from birth to five years old, if they've had an unprovoked seizure.

The effort could lead to Metafora's flow cytometry-based assay becoming the standard of care for diagnosing the disease in France.

Pages